Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study
Cemil Bilir, Ceyhun Varim, Hakan Cinemre, Ibrahim Yildiz, Ahmet Bilici, Mahmut Ucar, Veli Berk, Yasar Yildiz, Ozan Yazici, Goksen Inanc Imamoglu, Nuri Karadurmus, K. N. Pilanci, Erkan Arpaci, Ozgur Tanriverdi, Ebru Karci, Suleyman Temiz, Erdinc Nayir, Esin Oktay, Pinar Dal, Ibrahim Petekkaya
article (Uluslararası, Hakemli) | Yazar(lar): Cemil Bilir, Ceyhun Varim, Hakan Cinemre, Ibrahim Yildiz, Ahmet Bilici, Mahmut Ucar, Veli Berk, Yasar Yildiz, Ozan Yazici, Goksen Inanc Imamoglu, Nuri Karadurmus, K. N. Pilanci, Erkan Arpaci, Ozgur Tanriverdi, Ebru Karci, Suleyman Temiz, Erdinc Nayir, Esin Oktay, Pinar Dal,
Background: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35months (p < .001) and 21.0 versus 11.36months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively. Conclusions: The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC.